Copd Clinical Trial
Official title:
The Boundaries of Mild Chronic Obstructive Pulmonary Disease: Searching Clinical COPD Onset
The aim of this study is to determine if presence of dyspnea identifies differences in the 6-min walk test performance among smokers with normal or mild spirometric obstruction, accounting for the confounding effect of heart failure on dyspnea with stress echocardiography.
Chronic obstructive pulmonary disease (COPD) has a prolonged course before onset, following
classical epidemiological principles of chronic disease and genetic predisposition. "Disease
onset" may be defined as a physiologic impairment expressed by an abnormal spirometric index,
but "early disease" could include clinical manifestations, such as cough, phlegm, dyspnea or
exercise limitation, but normal spirometry. For the present proposal, we will use dyspnea to
define a symptomatic subject, since dyspnea is the most relevant symptom all over the range
of the disease. Besides, we have defined "early disease" when current or ex-smoker-adults: a)
complain of dyspnea but have normal spirometry; b) complain of dyspnea and have mild
bronchial obstruction; and, c) have mild bronchial obstruction without dyspnea. These
subtypes are roughly similar to Global initiative for Chronic Obstructive Lung Disease (GOLD)
stages 0 and 1 [1], although further characterized by the presence or absence of dyspnea. The
dyspnea cut off value we have chosen to separate symptomatic from asymptomatic subjects is a
modified Medical Research Council (mMRC) score ≥1, which is in line with several recent
communications [2-4], but differs from the cut off recommended by GOLD (score ≥2) [5]. In
addition, GOLD 0 stage [1], included in the GOLD guidelines of 2001 and currently not in use,
did not comprise a dyspneic subtype, which is now included in light of new evidence pointing
out at their potential relevance [6, 7].
Early disease subtypes
1. Symptomatic current or ex-smokers with normal spirometry have been reported by Woodruff
et al [7] on a large sample of individuals who complain of chronic respiratory symptoms,
reduced exercise tolerance, and computed tomography (CT) imaging bronchiolitis. These
results are in line with previous findings of another large study from Regan et al [8]
where more than 50% of symptomatic smokers with normal spirometry have
respiratory-related impairment and evidence of emphysema on CT imaging. Woodruff et al
[7] used the COPD Assessment Test (CAT) questionnaire to define symptoms [9] and found
that cough, phlegm, dyspnea, activity limitation, and energy level were equally
distributed among symptomatic smokers regardless of the presence of spirometric COPD.
However, although CAT is intended to be specific for COPD [9], most of its domains may
reflect concomitant respiratory (asthma and bronchiectasis) and/or nonrespiratory
diseases (heart failure, ischemic heart disease, obesity, and depression) [10]. In
contrast, Regan et al [8] measured seven "respiratory-related impairments" and found one
or more to be present in 54% of patients. Three of these impairments could be considered
rather specific of COPD, like CT percentage of emphysema >5% and gas trapping >20%, and
St. George's Respiratory Questionnaire (SGRQ) total score >25. However, four impairments
(chronic bronchitis, modified Medical Research Council (mMRC) dyspnea score ≥2,
exacerbations and 6-min walk distance <350 m) are non-specific as they may be partly or
fully explained by comorbidities like gastroesophageal reflux disease, rhinosinusitis,
obesity or heart failure, among others. Actually, retrospective data suggest that
patients with COPD and comorbid conditions may have greater risk for having symptoms
than those without comorbidity [11, 12].
2. Non-dyspneic current or ex-smokers with mild COPD has been also described [13, 14]. It
seems that in this group coexist individuals with normal lung function and 6-min walk
test performance [14] and subjects with resting lung hyperinflation, reduced diffusion
capacity of the lung for carbon monoxide (DLCO) and slightly increased
cycle-exercise-induced dyspnoea [13].
3. Dyspneic current or ex-smokers with mild COPD have significant emphysema and airway
thickness, lower DLCO, exercise-induced arterial desaturation, and reduced 6-min walking
distance [14, 15]. In addition, during incremental cycle-exercise they exhibit increased
ventilatory demand, lung hyperinflation and greater exertional dyspnea than smoker
controls [16].
Hypothesis
We hypothesize that dyspneic individuals notwithstanding of their spirometry results, should
share some clinical, structural and physiologic abnormalities. In particular, we expect that
the two dyspneic groups with and without mild COPD exhibit reduced exercise capacity, in
addition to worse quality of life; lower physical activity; greater lung hyperinflation;
greater emphysema and airway thickness; and reduced peripheral muscle mass, than their
asymptomatic counterpart, i.e., non-dyspneic mild COPD and controls.
Study aim
This study intends to identify the three early COPD subtypes already defined using
differences in exercise capacity as the primary outcome. As secondary outcomes, we will
intend to separate these groups by means of differences in clinical (quality of life,
physical activity), physiological (exercise testing) and structural characteristics
(emphysema, airway disease, and peripheral muscle mass by CT imaging). Future analyses are
planned to evaluate longitudinal deterioration in these clinical, physiological and
structural characteristics. Potential influence of obesity and undiagnosed heart failure on
dyspnea and thus, on exercise capacity, will be explored within the three subtypes.
Study design
The study has a cross sectional design aimed at obtaining representative samples of adults
between 45 and 80 years. Two hundred and forty participants will be enrolled into four strata
as already defined, i.e., dyspneic current or ex-smokers with and without mild COPD; and
non-dyspneic current or ex-smokers with and without (controls) mild COPD. Study subjects will
be recruited from the outpatient clinics and the pulmonary function labs at the Pontifical
Catholic University of Chile Health Network by means of physician referral, advertisement in
clinical areas, or self-referral at the study center. The Institutional Ethics Committee
approved the study protocol and signed informed consent will be obtained from all
participants.
Sample size
A sample size of at least 52 subjects per group provide enough power (80%) to detect a
significant difference (95% confidence level or alpha 0.05) in the 6-min walk test among
symptomatic and asymptomatic participants, based on a conservative relevant difference in
walking distance of 50 meters with a common standard deviation of 110 metres. Such difference
was found when comparing symptomatic and asymptomatic subjects with normal spirometry [7],
but may be an underestimation in patients with mild spirometric COPD [14], where the
difference between symptomatic and asymptomatic patients was 100 metres. Forestalling a
participant loss rate of 20%, 60 patients will be included in each group.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT06000696 -
Healthy at Home Pilot
|
||
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
||
Completed |
NCT04043728 -
Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study
|
N/A | |
Completed |
NCT04105075 -
COPD in Obese Patients
|
||
Recruiting |
NCT05825261 -
Exploring Novel Biomarkers for Emphysema Detection
|
||
Active, not recruiting |
NCT04075331 -
Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial
|
Phase 2/Phase 3 | |
Terminated |
NCT03640260 -
Respiratory Regulation With Biofeedback in COPD
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|
||
Withdrawn |
NCT04210050 -
Sleep Ventilation for Patients With Advanced Hypercapnic COPD
|
N/A | |
Terminated |
NCT03284203 -
Feasibility of At-Home Handheld Spirometry
|
N/A | |
Recruiting |
NCT06110403 -
Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT06040424 -
Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients
|
Phase 3 | |
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Recruiting |
NCT04868357 -
Hypnosis for the Management of Anxiety and Breathlessness During a Pulmonary Rehabilitation Program
|
N/A | |
Completed |
NCT01892566 -
Using Mobile Health to Respond Early to Acute Exacerbations of COPD in HIV
|
N/A | |
Completed |
NCT04119856 -
Outgoing Lung Team - a Cross-sectorial Intervention in Patients With COPD
|
N/A | |
Completed |
NCT04485741 -
Strados System at Center of Excellence
|
||
Completed |
NCT03626519 -
Effects of Menthol on Dyspnoea in COPD Patients
|
N/A | |
Recruiting |
NCT04860375 -
Multidisciplinary Management of Severe COPD
|
N/A |